Brief: Integra Lifesciences Q3 Adjusted EPS USD 0.41 Vs. IBES Estimate USD 0.39
04/11/2024 11:03
Nov 04 (Reuters) - Integra Lifesciences Q3 adjusted EBITDA USD 61.8 million vs. IBES estimate USD 59.7 million. * Q3 adjusted gross margin 63% * Q3 revenue USD 380.8 million vs. IBES estimate USD 375.8 million * Q3 adjusted net income USD 31.7 million vs. IBES estimate USD 30.4 million * outlook FY revenue USD 1,609-1,619 million
Recent news on Integra LifeSciences Holdings
See all newsIntegra LifeSciences Holdings Corporation reports results for the quarter ended September 30 - Earnings Summary
Integra Lifesciences Q3 revenue slightly misses estimates on flood damage
Brief: Integra Lifesciences - Enters Amended And Restated Credit Agreement On Oct 19, 2026 - SEC Filing
Brief: Integra Announces Completion Of Refinancing Transactions
Brief: Integra Announces Pricing Of Senior Secured Notes